Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Receivables (2017 - 2024)

Serina Therapeutics (SER) has disclosed Receivables for 8 consecutive years, with $65000.0 as the latest value for Q1 2024.

  • Quarterly Receivables rose 983.33% to $65000.0 in Q1 2024 from the year-ago period, while the trailing twelve-month figure was $65000.0 through Mar 2024, up 983.33% year-over-year, with the annual reading at $57000.0 for FY2023, 1325.0% up from the prior year.
  • Receivables hit $65000.0 in Q1 2024 for Serina Therapeutics, up from $57000.0 in the prior quarter.
  • In the past five years, Receivables ranged from a high of $406000.0 in Q1 2020 to a low of $1000.0 in Q3 2022.
  • Historically, Receivables has averaged $119625.0 across 5 years, with a median of $66000.0 in 2023.
  • Biggest five-year swings in Receivables: plummeted 98.95% in 2022 and later soared 6600.0% in 2023.
  • Year by year, Receivables stood at $397000.0 in 2020, then crashed by 76.07% to $95000.0 in 2021, then tumbled by 95.79% to $4000.0 in 2022, then soared by 1325.0% to $57000.0 in 2023, then increased by 14.04% to $65000.0 in 2024.
  • Business Quant data shows Receivables for SER at $65000.0 in Q1 2024, $57000.0 in Q4 2023, and $67000.0 in Q3 2023.